Risk of diabetes mellitus with atypical antipsychotic drugs;Risque de diabète sucré sous antipsychotiques atypiques

Medecine et Hygiene

Volumn 62, Issue 2493, 2004, Pages 1591-1596

  Scheen, André J ^a   De Hert, Marc ^b  

^a CHU SART TILMAN   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DIABETES MELLITUS; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HIGH RISK POPULATION; HUMAN; KETOACIDOSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 4544375814     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Freedman R. Drug Therapy. Schizophrenia. N Engl J Med 2003; 349: 1738-49.
2. Reynolds GP. What is an atypical antipsychotic. J Psychopharmacol 1997; 11: 195-9.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
4. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 2004; 64: 701-23.
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
6. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-65.
7. Baptisa T, Kin NMKN, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205-19.
8. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
9. Russel JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-51.
10. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28: 83-96.
11. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, qauetiapine or haloperidol: Results of the EIRE study. Schizophrenia Res 2003; 62: 77-88.
12. Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profiles of new antipsychotics: Public health consequences. Obesity Rev 2003; 4: 129-38.
13. Leucht S, Wagenpfeil S, Hamann J, Kissling W. Amisulpride is an «atypical» antipsychotic associated with low weight gain. Psychopharmacology 2004; 173: 112-5.
14. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43.
15. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002; 346: 591-602.
16. Henderson DC. Atypical antipsychotic-induced diabetes mellitus. How strong is the evidence? CNS Drugs 2002; 16: 77-89.
17. Hedenmalm K, Hägg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Safety 2002; 25: 1107-16.
18. Clark C, Burge MR. Diabetes mellitus associated with atypical antipsychotic medications. Diabetes Technol Ther 2003; 5: 669-83.
19. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs. Another high-risk group for type 2 diabetes. Diabetes Care 2003; 26: 1597-605.
20. Kohen D. Diabetes mellitus and schizophrenia: Historical perspective. Br J Psychiatry 2004; 184 (Suppl. 47): S64-6.
21. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during lanzapine use compared with risperidone use: A retrospective database analysis. J Clin Psychiatry 2002; 63: 1135-9.
22. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: Evidence from a large health plan database. J Clin Psychopharmacol 2003; 23: 328-35.
23. Semyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-6.
24. Wilson R, Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schiz Research 2002; 59: 1-6.
25. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716-23.
26. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-52.
27. Koller EA, Cross JT, Doraiswamy PM, Schneider BS, Risperidone-associated diabetes mellitus: A pharmacovigilance study. Pharmacotherapy 2003; 23: 735-44.
28. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: From the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23: 1123-30.
29. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003; 63: 116554.
30. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003; 58: 335-41.
31. Scheen AJ. Pathophysiology of insulin secretion. Ann Endocrinol (Paris) 2004; 65: 29-36.
32. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: The metabolic syndrome. Life Sciences 2002; 71: 239-57.